Efficacy of Helicobater pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: A systematic review.
Helicobacter pylori
chemo-immunotherapy
high-grade lymphoma
stomach
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
22
09
2022
received:
24
07
2022
accepted:
26
09
2022
pubmed:
30
9
2022
medline:
15
11
2022
entrez:
29
9
2022
Statut:
ppublish
Résumé
The role of Helicobater pylori eradication in the treatment of high-grade diffuse large B-cell lymphoma (DLBCL) of the stomach is unclear. We performed a systematic review and meta-analysis of currently available data. DLBCL-remission rate after eradication therapy, post-remission maintenance, and response rate in the case of additional oncological therapy were extracted. By considering data of seven studies, the DLBCL remission was achieved in 81 (53.3%; 95% CI = 45.3-61.2) out of 152 H. pylori eradicated patients. The regression rate did not differ between pure DLCBL and DLCBL with MALT component, between stage I and stage II disease, and between Caucasians and Asians. Disease regression was maintained in all patients after at a median of 63 months (range: 46-29) follow-up. In those non-responders, DLBLC remission after additional chemo-immunotherapy was achieved in 63 (98.4%; 95% CI = 95.4-100) out of 64 patients. Data this systematic review suggest considering H. pylori eradication as first-line therapy to treat infected patients with early-stage, high-grade gastric lymphoma.
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-647Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Peng JC, Zhong L, Ran ZH. Primary lymphomas in the gastrointestinal tract. J Dig Dis. 2015;16:169-176.
Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control. 2018;5:1073274818778256.
Matysiak-Budnik T, Fabiani B, Hennequin C, et al. Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). Dig Liver Dis. 2018;50:124-131.
Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (Suppl 6):vi144-vi148.
Seymour JF, Anderson RP, Bhatal PS. Regression of gastric lymphoma with therapy for Helicobacter pylori infection. Ann Intern Med. 1997;127:247.
Rudolph B, Bayerdorffer E, Ritter M, et al. Is the polymerase chain reaction or cure of Helicobacter pylori infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? J Clin Oncol. 1997;15:1104-1109.
Musshoff K, Schmidt-Vollmer H. Prognosis of non-Hodgkin's lymphomas with special emphasis on staging classification. Z Krebsforshung. 1975;83:323-328.
Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397-400.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712-716.
Huang WT, Kuo SH, Kuo YC, Lin CW. miR-155-regulated mTOR and Toll-like receptor 5 in gastric diffuse large B-cell lymphoma. Cancer Med. 2022;11:555-570.
Torisu T, Kawano S, Miyawaki K, et al. B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma. Hematol Oncol. 2021;39:145-147.
Ferreri AJ, Govi S, Raderer M, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood. 2012;120:3858-3860.
Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119:4838-4844.
Tari A, Asaoku H, Kashiwado K, et al. Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endosc. 2009;21:219-227.
Morgner A, Miehlke S, Fischbach W, et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol. 2001;19:2041-2048.
Nakamura S, Matsumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high-grade MALT lymphomas after eradication of Helicobacter pylori. Gut. 2001;48:454-460.
Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 2010;8:105-110.
Zullo A, Hassan C, Ridola L, et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol. 2013;47:824-827.
Carbone A, Gloghini A. Relationships between lymphomas linked to hepatitis C virus infection and their microenvironment. World J Gastroenterol. 2013;19:7874-7879.
Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59:169-177.
Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol. 2014;20:11054-11061.
Zullo A, Rago A, Felici S, Licci S, Ridola L, Caravita di Toritto T. Onset and progression of precancerous lesions on gastric mucosa of patients treated for gastric lymphoma. J Gastrointestin Liver Dis. 2020;29:27-31.